Tempest Therapeutics (NASDAQ:TPST) just reported results for the first quarter of 2024.
- Tempest Therapeutics reported earnings per share of -36 cents. This was above the analyst estimate for EPS of -39 cents.
- The company did not report any revenue for the quarter.